ArticleJournal of medicinal chemistry2012

Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.

Vassilios Bavetsias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.